Back to News
Market Impact: 0.25
Galderma Expands Relfydess Reach With China Approval For Frown Lines
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationProduct Launches
China's NMPA approved Galderma's Relfydess (relabotulinumtoxinA) for temporary improvement of moderate-to-severe glabellar lines in adults. The approval expands the product's regulatory availability in China; the article provides no financial figures or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
GALD0.65
More News
- With earnings in rearview mirror, SpaceX-Tesla merger chatter takes center stage
- Looters hit 3,000 French businesses. Within hours, the haul was trending on Vinted under the riot’s date
- Apple’s $2,000 iPhone Duo Debuts With Limited Supply
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- Oncologists Cheer Melanoma Data
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30